IMS Health Market Reflection Report for September 2016

IMS

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of the top companies, brands and therapy areas in the Indian Pharmaceutical Market.

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,278 crs in the month of September 2016 clocking a strong 10% growth over same period last year (SPLY). On a MAT September basis, the industry was valued at Rs. 111,022 crores and reflected a 13% growth with volumes contributing around 40% of this growth and New Introductions playing an important role with around 38% contribution to the overall growth.

The retail channel remained the largest channel in IPM contributing 84% of the overall sales and reflected a 13% growth. The hospital and doctor channel contributed to 10% & 6% of the overall sales and reflected a 17% & 15% growth respectively on a MAT September basis.

The retail channel remained the largest channel in IPM contributing 84% of the overall sales and reflected a 13% growth. The hospital and doctor channel contributed to 10% & 6% of the overall sales and reflected a 17% & 15% growth respectively on a MAT September basis. It is expected that the hospital channel will continue to report robust growth rates due to rapid capacity expansion in this space. As per IMS data which captures sales from trade stockists, more than 10 TAs in the IPM have already crossed a sale of Rs. 500 crores in the hospital segment viz. Anti Infectives, Cardiac, Gastrointestinals, Pain, Neuro, VMN, Gynae, Anti-diabetics, Vaccines & Respiratory.

IPM continued to remain fragmented with top 10 companies occupying 43% of the share and top 20 companies reflecting strong double digit growth for the month. Companies 31-40 collectively reflected a single digit growth on account of Himalaya (9%), Unique Pharma (9%) and Astra Zeneca (3%) which reflected a low growth.

Seven out of the top 10 companies reflected a double digit growth with Sun Pharma (11%), Cipla (11%), Alkem (16%), Macleods (18%), Lupin (15%) outpacing the market

Seven out of the top 10 companies reflected a double digit growth with Sun Pharma (11%), Cipla (11%), Alkem (16%), Macleods (18%), Lupin (15%) outpacing the market for the month while among the 11-20 companies, Aristo (17%), Glenmark (16%), USV (11%), Micro (15%) & IPCA (13%) grew faster than the market.

Among top 25 companies, Sun Pharma maintained its top position in the IPM with a market share of 7.84% and 11.4% growth, Intas gained 2 ranks and moved to 10th rank for the Month while Zydus and Novartis* gained 1 rank each and moved to 8th & 15th rank respectively vis-à-vis August 2016.

Domestic companies continued to dominate the market with a 79% share in Sep’16 with a growth of 11%. MNCs on the other hand reflected a growth of 6.5% for the month, after reaching a six month high growth of 12.5% in August.

Domestic companies continued to dominate the market with a 79% share in Sep’16 with a growth of 11%. MNCs on the other hand reflected a growth of 6.5% for the month, after reaching a six month high growth of 12.5% in August. Large MNCs like Abbott, GSK and Pfizer which contributed almost 57% of the total MNC share in the month reflected growths of 10%, 3% and 1% respectively.

Acute therapies remained the strongest pillar of IPM with a 66% contribution to the total market. After reaching a 12 month high of 20% growth in August 2016, acute TAs reflected a slowdown with a 9.5% growth for the month of Sep 2016. Chronic TAs on the other hand outpaced acute TAs reflecting a growth of 11% for the month.

AI was by far the largest TA for the month with a revenue of Rs. 1542 crores reflecting a 10% growth on the back of a good monsoon witnessed across the country. This was an impressive performance considering 14% of the portfolio impacted by the FDC ban

AI was by far the largest TA for the month with a revenue of Rs. 1542 crores reflecting a 10% growth on the back of a good monsoon witnessed across the country. This was an impressive performance considering 14% of the portfolio impacted by the FDC ban comprised of anti-infectives while it was also one of the largest TAs to be affected by the NLEM notification. Top 10 anti-infective molecules reflected an average growth of 16% for the month with Amoxyclav liquids, Cefpodoxime, Meropenem & Cefixime + Oflox combination reflecting superlative growth of 25%, 20%, 19% & 17% respectively.

Cardiac TA maintained its no. 2 position in IPM by a whisker beating GI with a value of Rs. 1103 crores for the month of Sep’16 growing at 6%. The TA was driven by Rosuvastatin (11% gwth), Amlodipine+ Telmisartan (13% gwth) and Olmesartan (10% gwth). Telmisartan which recently came under price control reflected a -2% growth for the month.

Gastrointestinals continued to be the 3rd largest TA for the month garnering a revenue of Rs. 1064 crores with a growth of 8%. PPIs and their combination with Domperidone reflected strong double digit growth. Rabeprazole + Domperidone, Pantoprazole + Domperidone and ranitidine were among the fastest growing molecules with a growth of 11%, 10% and 17% respectively. Lactulose reflected a healthy 31% growth for the month clocking a value of Rs. 29 crores.

Respiratory was the 4th largest TA for the month maintaining its rank gain and clocked an 18% growth over SPLY. Cough preparations, Levosalbutamol combinations, Budesonide and Levocetirizine were among the fastest growing categories in the respiratory space reflecting growth of 16%, 95%, 26% and 23% respectively.

Dermtology was one of the fastest growing TAs for the month registering a growth of 15% SPLY with a value of Rs. 691 crores. Anti- fungals reflected a good pick up during the monsoon season with top molecules like Itraconazole, Terbinafine & Clortimazole growing at 126%, 26% and 17% respectively. Emollients continued to be the largest category within dermatology reflecting a 14% growth for the month.

Among chronic TAs, Anti-Diabetic, Urology & Neurology were among the fast growing TAs, growing at 17% & 11% & 10% for the month respectively. DPP4 inhibitors driven by teneligliptin and the unprecedented number of players it has got into the market and glim+ met formulations spearheaded growth for the AD market. In the neurology space Levetiracetam continued to be the fastest growing molecule in neuro psychiatry for the month clocking a value of Rs. 43 crs with a growth of 20% in Sep 2016. Betahistine & Escitalopram + Clonazepam found place among the fastest growing CNS molecules for the month with a growth of 14% and 13% respectively.

In terms of New Introductions (NI 24 months) which played a crucial role in growth of the IPM, Glenmark had the highest number of NIs (4 Nos.)

In terms of New Introductions (NI 24 months) which played a crucial role in growth of the IPM, Glenmark had the highest number of NIs (4 Nos.) among the top 25 NIs in the industry for the month of Sep’16, followed by Macleods (3 Nos.), J&J, MSD & Hamdard with 2 NIs each featuring among the top 25.

Sr. No

BRANDS PROD_LNCH COMPANY Sep 2016 Val (Rs. Crs)

1

PANDERM NM

201605 MACLEODS PHARMA 6.2

2

RYZODEG FLEXTOUCH 201412 ABBOTT 6.2

3

CARIPILL

201507

MICRO LABS

5.1

4

FORXIGA 201505

ASTRAZENECA

5.0

5

IT-MAC 201510 MACLEODS PHARMA 4.9
6 JARDIANCE 201510 BOEHRINGER INGELH.

4.7

7

ASCORIL-D 201503 GLENMARK PHARMA 4.5
8

ONE TOUCH SELECT

201501

JOHNSON & JOHNSON

4.4

9 VARIPED 201503 MSD PHARMACEUTICA

4.1

10

ZITA-MET PLUS 201509 GLENMARK PHARMA

4.0

11

INSTAKIT 201604 MACLEODS PHARMA 3.8
12 GONAL-F 201509 MERCK LIMITED

3.4

13

INVOKANA 201503 JANSSEN 3.1
14

SAFI

201506

HAMDARD

3.1

15

ONE TOUCH ULTRA 201501 JOHNSON & JOHNSON 3.0
16 SULISENT 201510 U S V

2.9

17

TERBINAFORCE-LITE 201607 MANKIND 2.9
18 ZITA PLUS 201506 GLENMARK PHARMA

2.7

19

AXCER 201510 SUN 2.7
20 AMBRODIL-S PLUS 201608 ARISTO PHARMA

2.6

21

ONDERO 201512 LUPIN LIMITED 2.5
22 ZITEN-M 201509 GLENMARK PHARMA

2.2

23 JANUMET XR 201410 MSD PHARMACEUTICA

2.2

24

BGR-34 201510 AIMIL

2.2

25

SUALIN 201506 HAMDARD 2.1

Global Outlook (August 2016)

The global Pharmaceutical market is valued at US $ 957 Billion growing at 1%. USA, being the market leader with 47% share and growth of 5%.

Amongst the top 15 market, India is ranked 10th and growing at 15% for the month of August and 7% in the MAT year ending Aug 2016.

Table 1: Pharma Market Size in Mn $ USD by Country

All values in Million USD

Aug Month Month Growth % Aug MAT MAT growth %
Global Pharma Mkt 73043 1.2 957084

3.5

USA

34726 5.2 443724 7.8

JAPAN

6900 22.5 79180

8.6

CHINA 6315 7.3 73986

0.4

GERMANY

3424 13.9 40295 -0.4

BRAZIL

1995 26.6 19158

-11.6

UK 1949 -5 25330

0.6

CANADA

1696 11 19143 -4.5
FRANCE 1663 -29.2 31928

-5.2

VENEZUELA

1653 57.9 15293 33.1

INDIA

1424 15.1 15064

7

AUSTRALIA 1244 38.6 12182

7.2

ITALY

821 -56.2 27340 1.9
SPAIN 820 -45 20286

1

Indian companies holds 4.3% share in the global market and growing faster than the global market. The share of Indian companies has grown due to higher demand generation in India on account of rainy season. Amongst the top 5 Indian companies, Lupin is growing at 37% while Cipla at 23% and Sun Pharma at 15% respectively in the month of August.

Table 2: Indian companies Market Size in the Global Market

All values in Million USD

Aug Month Month Growth % Aug MAT MAT growth %

Indian companies market size

3160 11.2 36712

7.1

SUN PHARMA 448 15 5264

5.2

LUPIN

335 37 3874 20.8

DR REDDYS LAB

239 -4.1 3073 -3

CIPLA

177 22.7 1815

8.9

ZYDUS CADILA 176 3.7

2052

-2.3

TORRENT 174 11.1 1939

8

AUROBINDO

156 0.9 2269 3.9
GLENMARK PHARM 152 11 1760

5.9

INTAS

122 -8 1745 13.7

ALKEM

110 23.5 1103

11.8

MANKIND PHARMA 107 17.4 1115

13.9

MACLEODS PHARMA

97 27.2 999

10.7

IPM Snapshot

TSA = Total Sales Audit which includes Hospital, doctor and retail channels

SSA = Secondary Sales Audit which is retail channel sales from the local pharmacy retailers

About IMS Health

IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance.
  • Priyanka Sawant

    Hello,

    can you please let us know when will you publish the next reflection report Dec 2016 or Jan 2017.

    Thanks,
    Priyanka

  • Navin Jalwania

    Eye opener data…Thank you

MENU
%d bloggers like this: